Small molecule aptamer selection is widely regarded as the most demanding application of SELEX (Systematic Evolution of Ligands by Exponential Enrichment). A protein target offers a broad surface on which an aptamer can form multivalent contacts, whereas small molecules — amino acids, toxins, antibiotics and metabolites — have molecular weights of only a few hundred daltons and present a very limited chemical space for nucleic acid recognition. They frequently lack multiple functional groups that can be derivatized, so immobilization can readily mask the very epitopes required for binding, or yield sequences that recognize the target-carrier conjugate rather than the free target in solution. Whether a selection succeeds therefore depends on applying enough selection stringency without disturbing the target's native conformation. Below we discuss selection pressure, immobilization formats and counter-selection design in small molecule SELEX, and set out a representative workflow and timeline.
The difficulty is not simply low molecular weight. When a target small molecule and its structural analogs differ by a single hydroxyl group, a single amino group, or the position of one methyl group, the enriched pool tends to converge on the shared scaffold instead of discriminating the atoms that differ. Two strategies address this.
Strategy 1: dynamic selection stringency guided by enrichment data. Adjust the pressure round by round according to the validation and enrichment profile of the aptamers recovered in each round. The amount of library input, incubation time, number and stringency of washes, elution conditions and PCR cycle number are all tunable. At the same time, introduce negative selectors, including bare magnetic beads and structural analogs. Over successive rounds, sequences that make direct contact with the positions that differentiate the target from its analogs are preferentially retained, while weakly binding or scaffold-recognizing sequences are depleted by counter-selection.
Strategy 2: expand the chemical alphabet of the library. A small molecule offers too few handles for hydrogen bonding and base stacking, and the four natural bases provide limited recognition capacity. Click-Capture SELEX incorporates chemically modified nucleotides such as indole-dU into the library, supplying additional aromatic rings and hydrogen-bond donors for target engagement. In a selection against kanamycin A, the indole modification yielded aptamers able to distinguish kanamycin A from kanamycin B — a single amino/hydroxyl difference — with a KD of 6 μM and no appreciable binding to the structural analog. The single-atom discrimination problem in small molecule aptamer selection therefore sometimes has to be solved at the level of library chemistry rather than by changing the selection protocol.

Figure 1. Workflow of Click-Capture SELEX against small-molecule targets.
Choosing an Immobilization Format: Magnetic Beads, Affinity Columns or Free-Target Selection
For a small molecule, any chemical coupling may occupy the few recognition sites available on its surface. The three principal small-molecule immobilization strategies compare as follows.
Magnetic bead immobilization. This is the most widely used format in small molecule SELEX: handling is simple and magnetic separation is fast. The drawback is that the target is coupled covalently to the bead surface, so recovered sequences may recognize the linker-target composite interface rather than the free molecule. For example, when THCA was chemically derivatized and immobilized on beads for click-SELEX, the resulting aptamers bound both THCA and THC, but with markedly lower affinity for THC. The effect was attributed to a neo-epitope introduced by immobilization and to an altered electron distribution in the target. If the intended application is the detection of free small molecules, such aptamers may fail in real samples.
Affinity column immobilization. Columns permit more rigorous washing and better-controlled competitive elution. Column-based SELEX allows displacement with a high concentration of free target during elution, which in principle preferentially releases sequences that genuinely bind the unmodified small molecule. Preparing a small-molecule column, however, requires a relatively large amount of target and a suitable coupling chemistry, which is impractical for scarce or precious samples.
Free-target (solution-phase) selection. This is the definitive route to eliminating immobilization bias, and the most difficult to implement. In Capture-SELEX the library, not the target, is held on the solid phase, and the target is added in free form. Library sequences are retained on magnetic beads through hybridization between a docking sequence and a capture oligonucleotide. When a sequence binds the free target, the resulting conformational change releases it from the capture strand into solution, where it is recovered. The approach avoids target modification altogether, but it depends on precise tuning of the conformational switch during library design, and not every sequence dissociates efficiently upon target binding.
Counter-selection in small molecule SELEX has to remove both sequences that bind the solid support and sequences that bind structural analogs. Streptavidin (SA) magnetic beads are the most commonly used solid phase. Before every round of positive selection, incubate the library with unmodified (bare) beads to deplete aptamers with affinity for the bead matrix itself. The design of analog counter-selection matters just as much: which analog to use, in which round to introduce it, at what concentration, how long to incubate the target with the library, and how many PCR cycles to run on the enriched pool should all be adjusted dynamically on the basis of sequence validation results from each round. Excessively stringent counter-selection applied over several rounds can eliminate every binding sequence.
Step | Content | Duration |
Step 1: Small-molecule modification | Biotinylation of the target small molecule | 3-4 weeks |
Step 2: Aptamer selection (SELEX) | Six rounds of selection (SA bead structural-analog counter-selection plus SA bead small-molecule positive selection) followed by next-generation sequencing (NGS) | 8-10 weeks |
Step 3: Aptamer synthesis and validation | Aptamer synthesis, EC50 determination and BLI/SPR validation | 2-3 weeks |
Total | Full workflow from target modification to validated aptamers | 13-17 weeks |

Figure 2. Tek Biotech aptamer selection workflow.
Tek Biotech (Tianjin) Co., Ltd. provides high-affinity, high-specificity aptamer selection services that support downstream development, including aptamer functional validation (affinity measurement, competitive ELISA, in vitro cell-based functional assays such as target recognition and inhibition and flow cytometry-based blockade, and in vivo functional studies such as targeted inhibition and signaling pathway blockade) and the development of therapeutics directed at specific molecular targets.
![]() | Small-Molecule Aptamer Selection: Overcoming SELEX Challenges, Immobilization Bias and Timeline Constraints |
![]() | Choosing an Affinity Assay for Nanobodies: SPR vs. BLI |
![]() | Empowering Precision Medicine: The "Magic Scissors" and "Master Strokes" of Antibody Engineering |
![]() | Humanization calculation method and structural feature analysis of nanobodies! |
![]() | Stop Sticking with Hybridoma! A Primer on the Three Generations of Antibody Discovery Technology |
![]() | Rationale and Significance of Bispecific Antibody Development |
![]() | Protein Not Expressing? You Might Have Chosen the Wrong Tag! |
![]() | What to Do After Protein Purification? These Four Validation Methods You Must Know! |
To experience the reliable service of Tekbiotech please subscribe:
Antibody Discovery
Antibody Production
Antibody Modification
Contact
Follow us!
Technical Support
©2026Tekbiotech (Tianjin) Co., Ltd